Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas
Authors
Keywords
Advanced or metastatic leiomyosarcoma, Benchmark, Efficacy, Meta-analysis, Study design
Journal
EUROPEAN JOURNAL OF CANCER
Volume 154, Issue -, Pages 253-268
Publisher
Elsevier BV
Online
2021-07-21
DOI
10.1016/j.ejca.2021.06.025
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine
- (2020) Adriana C. Gamboa et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation
- (2019) Kazuhiro Tanaka et al. BMC CANCER
- Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2018) P G Casali et al. ANNALS OF ONCOLOGY
- A review of soft-tissue sarcomas: translation of biological advances into treatment measures
- (2018) Ngoc T Hoang et al. Cancer Management and Research
- Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
- (2017) Beatrice Seddon et al. LANCET ONCOLOGY
- Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
- (2017) William D Tap et al. LANCET ONCOLOGY
- Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†
- (2016) Akira Kawai et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
- (2016) Christopher W. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
- (2016) Patrick Schöffski et al. LANCET
- Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Olivier Mir et al. LANCET ONCOLOGY
- A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
- (2015) Z Eroglu et al. BRITISH JOURNAL OF CANCER
- SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
- (2015) Scott M. Schuetze et al. CANCER
- Clinically Relevant Molecular Subtypes in Leiomyosarcoma
- (2015) X. Guo et al. CLINICAL CANCER RESEARCH
- Meta-analysis in clinical trials revisited
- (2015) Rebecca DerSimonian et al. Contemporary Clinical Trials
- A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial
- (2015) B. Bui-Nguyen et al. EUROPEAN JOURNAL OF CANCER
- Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study
- (2015) Martee L. Hensley et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial
- (2015) Patricia Pautier et al. LANCET ONCOLOGY
- Conducting Meta-Analyses inRwith themetaforPackage
- (2015) Wolfgang Viechtbauer Journal of Statistical Software
- A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group Study
- (2014) Linda R. Duska et al. GYNECOLOGIC ONCOLOGY
- Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
- (2014) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
- (2014) Ian Judson et al. LANCET ONCOLOGY
- A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
- (2013) P A Cassier et al. BRITISH JOURNAL OF CANCER
- An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
- (2013) P. Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study
- (2013) H. Gelderblom et al. EUROPEAN JOURNAL OF CANCER
- WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition
- (2013) Vickie Y. Jo et al. PATHOLOGY
- Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy
- (2012) A. Santoro et al. ANNALS OF ONCOLOGY
- Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
- (2012) Scott M. Schuetze et al. EUROPEAN JOURNAL OF CANCER
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)
- (2012) P. Pautier et al. ONCOLOGIST
- Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
- (2011) Xavier García-del-Muro et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
- (2011) Patrick Schöffski et al. LANCET ONCOLOGY
- Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy
- (2009) N. Penel et al. ANNALS OF ONCOLOGY
- Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
- (2009) Martee L. Hensley et al. GYNECOLOGIC ONCOLOGY
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
- (2008) Martee L. Hensley et al. GYNECOLOGIC ONCOLOGY
- Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial
- (2008) Martee L. Hensley et al. GYNECOLOGIC ONCOLOGY
- Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry
- (2008) Jaime L. Peters et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search